RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Invited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

Commentary on Twitter

Just published @TheLancet
A randomized mix and match trial of AZ and Pfizer vaccination in >800 people shows that mixing is safe and can engender at least as good, if not better, immune response https://t.co/V40Dy59Ia8 by @XinxueLiu and colleagues pic.twitter.com/tKl59LFz4i

— Eric Topol (@EricTopol) August 6, 2021